Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone

AUTOR(ES)

Singh, Sheldon M.

RESUMO

INFLIXIMAB IS A CHIMERIC ANTI-TUMOUR NECROSIS FACTOR-α antibody that is efficacious in treating Crohn's disease. However, its immunomodulatory properties increase susceptibility to opportunistic infections. We present a case of cutaneous Nocardia infection in a patient who was taking infliximab for Crohn's disease. The case illustrates the challenges in the diagnosis and management of this disease and serves as a reminder of the complications associated with the use of immunomodulatory agents.

Documentos Relacionados

• Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease
• Gummatous cutaneous tuberculosis associated with the use of infliximab for Crohn's disease,
• Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
• Metastatic Crohn’s disease despite infliximab therapy
• Infliximab and adalimumab‐induced thrombocytopenia in a woman with colonic Crohn's disease